Topics Covered
- Controlling cancer
- p53 discovery
- Oncoproteins
- SV40, Adeno and HPV
- The p53 protein
- Incidence of genetic changes in p53 in human cancers
- What does p53 do?
- The p53 pathway is blocked in many tumor cells
- p53 and HDM2 are connected by a negative feedback loop
- Mdm2 controls p53
- Evidence for the fine regulation of the p53 response
- How does p53 cause advanced aging?
- Therapy approaches
- Gene therapy
- Activating p53
- Targets for p53 activation
- Small peptides block p53/HDM interaction and activate p53
- Peptide minimization and optimization
- Nutlin 3 specificity
- Thousands of compounds can be tested for their ability to activate p53-dependent transcription
- CYC202: a cdk inhibitor in clinical trial that is a non genotoxic activator of the p53 response
- CDK inhibition
- Regulation of p53 by ubiquitin like proteins
- Stress stimuli that control the activity of p53
- New isoforms of p53
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Lane, D. (2009, June 28). Drug discovery and target validation in the p53 pathway [Video file]. In
The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved August 20, 2022, from
https://hstalks.com/bs/1271/.
Publication History
-
Published on June 28, 2009
Financial Disclosures
- Prof. Sir David Lane has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.